MOBILISATION OF HAEMATOPOIETIC STEM CELLS IN PAEDIATRIC PATIENTS, PRIOR TO AUTOLOGOUS TRANSPLANTATION FOLLOWING ADMINISTRATION OF PLERIXAFOR AND G-CSF

Previous chemotherapy and radiation exposure can make adequate stem cell mobilisation prior to autologous transplant extremely difficult in paediatrics. Plerixafor, a selective reversible CXCR4 antagonist interferes with CXCR4 interaction with Stromal cell-derived factor 1 alpha (SDF-1). Combination with granulocyte-colony stimulating factor (G-CSF) amplifies G-CSF affects in mobilising haematopoietic stem cells. Whilst licensed for use with G-CSF for enhancement of mobilisation of haematopoietic stem cells in adults, paediatric data for use of plerixafor remain limited. We present a retrospective review of outcomes seen with plerixafor and G-CSF to mobilise stem cells heavily pre-treated paediatric patients with cancer. Pediatr Blood Cancer 2015;62:1477-1480. (c) 2015 Wiley Periodicals, Inc.